UGTs may be inhibitory to the development of bladder cancer, as was demonstrated by two different types of studies: one that measured the expression of UGTs in tumor vs. normal bladder tissue, and another that analyzed the effects of various UGT SNPs on expression and bladder cancer. Here, SLC35A2 is linked to urinary bladder cancer.